AlphAIalphai — Financial news for AI agents
yahoo.comAUG 155 min read$CELC

Celcuity Q2 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported Q2 earnings call highlights for its gedatolisib programs. In REVTORPYK, adverse-event discontinuations were 5.2% (mutant cohort) for the triplet and 3.8% for the doublet, versus 19% for alpelisib. The company is expanding VIKTORIA-2 and advancing a prostate Phase Ib/II trial with darolutamide. Q2 net loss was $78.9M ($1.44/share). Cash totaled $754M.

Original reporting
yahoo.com
Published Aug 15, 2026, 6:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 15, 2026, 6:44 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Celcuity Q2 Earnings Call Highlights — source image
Source · yahoo.com
Decision brief

The 30-second read

$CELCNeutralMed
01

Why it matters

Traders can update probabilities around launch execution (expanded-access shipping, second-site FDA clearance timeline) and near-term clinical risk (adverse-event discontinuation rates in mutant vs wild-type cohorts). The Q2 cash position and convertible note proceeds also inform financing overhang into 2029.

02

Market read

The article combines Q2 financials, safety/tolerability discontinuation rates for REVTORPYK, and a concrete late-Q3 manufacturing shipment expectation, which together can move biotech risk pricing.

03

What to watch

SG&A surge for pre-launch and ongoing cash burn could increase financing/dilution risk, partially offsetting the de-risking narrative from manufacturing-site validation and expanded-access shipping.

Relevance 7/10Novelty 6/10Timing: pre-market today, with late-Q3 shipment confidence and Q2 financials driving near-term positioning

Background

Celcuity is preparing commercial launch for REVTORPYK and expanding its first-line breast cancer and prostate cancer programs for gedatolisib-based combinations.

Company-level read

Ticker impact

$CELCNeutralMedium confidence
Context

Celcuity disclosed Q2 results plus REVTORPYK adverse-event discontinuation rates and plans to ship late Q3 after FDA clearance for a second manufacturing site.

Expected impact

Moderate upside bias if investors view discontinuation rates and late-Q3 shipping confidence as de-risking launch; downside risk if cash burn and SG&A ramp raise dilution concerns.

Evidence & confidence

The article adds multiple decision-relevant datapoints (trial discontinuation rates, expanded-access shipping, and manufacturing-site clearance timeline) but does not provide a new efficacy endpoint or explicit guidance that would likely dominate valuation immediately.

Market effects

Sector

Highlights how safety tolerability and manufacturing readiness can become key trading drivers for precision oncology launches.

Regional

Primarily US biotech sentiment, with no direct regional macro linkage.

Global

Limited global spillover beyond oncology peers watching similar PI3K/targeted-therapy tolerability and supply timelines.

Counterpoint

What could challenge this read

Discontinuation due to adverse events may not translate into durable efficacy or regulatory/label confidence; investors may discount safety-only signals without mature PFS/response.

Key entities

  • company
    Celcuity

    Clinical-stage precision oncology company developing gedatolisib programs and preparing REVTORPYK launch.

  • program
    REVTORPYK

    Second-line breast cancer program with reported adverse-event discontinuation rates and launch preparation details.

  • program
    VIKTORIA-2

    First-line breast cancer expansion evaluating gedatolisib combinations in endocrine-sensitive and endocrine-resistant settings.

  • drug
    gedatolisib

    Targeted oncology agent used in multiple combination trials discussed in the call.

  • regulator
    FDA

    Second manufacturing site requires FDA clearance before shipments can begin.

Read at source← All news

Related articles

AUG 13
$CELCMedAI 8/10

Celcuity Inc. (CELC): Results of Operations and Financial Condition

Celcuity Inc. (CELC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 celc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update • REVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or meta

SEC EDGAR 8-K7 min
AUG 1
$CELCMed

Newly FDA-approved Revtorpyk wins NCCN listing

Celcuity (NASDAQ: CELC) said its Revtorpyk (gedatolisib) plus fulvestrant, with or without palbociclib, was added to NCCN Guidelines as a preferred Category 1 option for HR+, HER2- advanced or metastatic breast cancer after endocrine therapy progression. FDA approved Revtorpyk on July 14, 2026 for HR+/HER2- disease without detected PIK3CA mutation.

thepharmaletter.com4 min
JUL 24
$CELCMedAI 9/10

REVTORPYK (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Breast Cancer, US

Celcuity’s REVTORPYK (gedatolisib) was approved by the US FDA in July 2026 for HR+/HER2- locally advanced or metastatic breast cancer with PIK3CA wild-type, in combination with fulvestrant, with or without palbociclib, after progression on endocrine therapy. VIKTORIA-1 (n=392) showed arm A median PFS 9.3 vs 2.0 months for fulvestrant alone, ORR 32% vs 1%. Commercial launch planned for late Q3 2026.

clinicaltrialsarena.com6 min
JUL 23
$CELCMedAI 8/10

Celcuity faces securities fraud probe

Pomerantz LLP says it is investigating Celcuity Inc. for possible securities fraud after Celcuity announced a delayed commercial launch for its FDA-approved breast cancer drug Revtorpyk. The launch was pushed to late Q3 2026, later than analysts expected, and Celcuity shares fell 17.6% on July 15, 2026. The probe concerns whether the delay involved unlawful practices.

pluang.com3 min
JUL 22
$CELCMedAI 8/10

Celcuity (CELC) Is Down 17.4% After FDA Clears First-in-Class REVTORPYK Combo for HR+ Breast Cancer

Celcuity (Nasdaq: CELC) said the FDA approved REVTORPYK (gedatolisib) with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation after at least one endocrine therapy line. The VIKTORIA-1 data showed a progression-free survival benefit, with higher stomatitis, rash and metabolic side effects. The stock was reported down 17.4%.

simplywall.st6 min
Celcuity Q2 Earnings Call Highlights — alphai